Gilead enters deal with Yuhan to develop drugs for advanced fibrosis due to NASH

Gilead Sciences entered an agreement with Yuhan to co-develop therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH), the companies announced. Under the deal, Gilead will make an upfront payment of $15 million to Yuhan, with the latter eligible to receive up to an additional $770 million in milestones, as well as royalties on future net sales.

The drugmakers noted that as part of the agreement, Gilead will acquire global rights to develop and commercialise small molecules against two undisclosed targets in all countries, with the exception of South Korea, where Yuhan will retain certain marketing rights. The companies will jointly conduct preclinical research, and Gilead will be responsible for global clinical development and commercialisation outside of Yuhan's rights in South Korea.

"This collaboration builds on our long-term partnership with Yuhan, with a new focus on the investigation of novel approaches to treat patients with advanced fibrosis due to NASH that complement our ongoing research programmes," remarked Gilead head of R&D John McHutchison.

Last month, Gilead entered a deal with Scholar Rock to discover and develop highly specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. For further analysis, read ViewPoints: Gilead, Scholar Rock look for the next best thing in fibrosis.

To read more Top Story articles, click here.